Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
GTBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $4.10
Previous CloseN/A
Volume15.05K
Average Volume (3M)300.75K
Market Cap
$2.65M
Enterprise Value$6.56M
Total Cash (Recent Filing)$5.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Nov 04, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding3,557,502
10 Day Avg. Volume687,001
30 Day Avg. Volume300,746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$11.00Price Target Upside1275.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.63 and its highest was $4.10 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $2.65M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Nov 04, 2025 which is in 51 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.13.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.38.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 3,557,502 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went down -7.586%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
Company Description
GT Biopharma
GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies based on its proprietary TriKE (Tri-specific Killer Engager) platform. Operating in the biotechnology and pharmaceuticals sector, the company is dedicated to the discovery and development of immuno-oncology products designed to harness and enhance the body's natural immune system to target and destroy cancer cells. GT Biopharma's core product candidates aim to address various hematologic malignancies and solid tumors, offering a novel approach to cancer treatment.
Technical Analysis
Brainstorm Cell Therapeutics
―
Genprex
―
Aptorum Group
―
Lyra Therapeutics
―
Conduit Pharmaceuticals
―
Ownership Overview
―
Insiders
0.95% Mutual Funds
<0.01% Other Institutional Investors
98.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---